Title: Direct
Conversion of Pluripotent Human Embryonic Stem Cells into Functional Human Neuronal or Cardiomyocyte Cell Therapy
Derivatives for Regenerative Medicine
Abstract: Given the limited capacity of CNS
and heart for self-repair/renewal, cell-based therapy represents a promising
therapeutic approach closest to provide a cure to restore normal tissue and
function for neurological and cardiovascular disorders. Derivation of human
embryonic stem cell (hESCs) from the in
vitro fertilization (IVF) leftover embryos has brought a new era of
cellular medicine for the damaged CNS and heart. Recent advances and technology
breakthroughs in hESC research have overcome some major obstacles in moving
stem cell research from animals towards humans trials, including resolving
minimal essential human requirements for de novo derivation and
long-term maintenance of clinically-suitable stable hESC lines and direct
conversion of such pluripotent hESCs into a large supply of clinical-grade
functional human neuronal or cardiomyocyte cell therapy products. Such
breakthrough stem cell technologies have demonstrated the direct pharmacologic
utility and capacity of hESC cell therapy derivatives for human CNS and
myocardium regeneration and, thus, have presented the hESC cell therapy
derivatives as a powerful pharmacologic agent of cellular entity for CNS and
heart repair. The availability of human stem/progenitor/precursor cells in high
quality and large commercial scales with adequate cellular neurogenic or
cardiogenic capacity will greatly facilitate developing safe and effective
cell-based regenerative therapies against a wide range of CNS and heart
disorders. Transforming non-functional pluripotent hESCs into fate-restricted
functional human cell therapy derivatives dramatically increases the clinical
efficacy of graft-dependent repair and safety of hESC-derived cellular products,
marking a turning point in cell-based regenerative medicine from current
studies in animals towards human trials.
No comments:
Post a Comment